CD8A and neoplasm: High-resolution scRNA-seq allows precise analysis of cellular heterogeneity in the tumor immune microenvironment, identifying biomarkers like high PD-1 expression on CD8+ T cells, indicating an exhausted state linked to responsiveness to anti-PD-1/PD-L1 therapy (56, 58–60).